Relationship Between Serum Levels Of SICAM-1, IGF-1 And Cognitive Impairment In Patients With Subcortical Ischemic Vascular Disease

Objective To detect serum levels of soluble intercellular adhesion molecule 1(sICAM-1), insulin-like growth factor 1 (IGF-1) in patients subcortical ischemic vascular disease (SIVD), and to explore the relationship between serum sICAM-1, IGF-1 and cognitive impairment of SIVD.Methods 54 patients who were diagnosed SIVD were selected from October 2014 to February 2015 in Anhui Provincial Hospital of Neurology outpatients and hospitalized patients, aged 35 to 85 years old.22 cases of subcortical vascular dementia (SVaD) and 32 cases of subcortical vascular cognitive impairment(SVMCI) consisted of SIVD group. The control group were recruited for the same period in our hospital for treatment of dizziness and other symptoms, and there was no evidence of cerebrovascular disease, aged 47 to 81 years. Clinical date of all participants was collected in detail, including history of hypertension, age, education, smoking history, drinking history, history of diabetes. All subjects were arranged to detect routine biochemical indicators, including triglycerides(TG), total cholesterol(TC), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (HDL-C). Fasting serum samples were collected and double antibody sandwich was used to detect serum sICAM-1, IGF-1 levels. Serum sICAM-1, IGF-1 levels were compared in three groups. All selected candidates were tested by neuropsychological scale, including Montreal Cognitive Assessment Scale(MoCA), Clinical Dementia Scale (CDR), Activity of Daily Living Scale (ADL), Hamilton Depression Scale (HAMD). The relationship was analyzed between MoCA scales and serum sICAM-1, IGF-1. Multiple linear regression analysis was applyed to analyze the relationship of cognitive impairment in subcortical ischemic vascular disease(SIVD) and factors.Results 1.Serum sICAM-1 levels in the control group, SVMCI group and SVaD group were 333.42±93.68 ng/L,392.39±114.98 ng/L and 429.00±121.25 ng/L. Serum sICAM-1 levels in control group were significantly lower than the SVaD group and SVMCI group (P <0.05). There was no significant difference between SVaD group and SVMCI group (P> 0.05).2.Serum IGF-1 levels in the control group, SVMCI, SVaD group were 270.89±75.71μg/L,229.70±76.53μg/L and 215.68±72.81Lg/L. Serum IGF-1 levels in control group were significantly higher than those in SVaD group and SVMCI group (P<0.05). There was no statistically significant difference between SVaD group and SVMCI group. (P>0.05).3.Cognitive domain scores of MoCA scale were compared between the control group and SVMCI group.The differences in visuospatial and executive function, attention, abstract thinking and delayed memory were significant in two groups(P<0.05). Cognitive domain scores of MoCA scale were compared between the control group and SVaD group. There were significant differences in visuospatial and executive function, attention, language, abstract thinking, delayed memory and orientation in two groups(P<0.05).4.Spearman correlation analysis showed that MoCA scores and serum IGF-1 levels were positively correlated (r=0.332, P=0.002), while serum sICAM-1 levels were no signficant correlated (r=-0.186, P=0.092). Multiple linear regression analysis showed that MoCA scores and hypertension, education, IGF-1 levels were significantly correlated after controlling for age, hyperlipidemia, diabetes, smoking, drinking, etc.Conclusion Serum IGF-1 levels are positively related to cognition in patients with SIVD, while there are no significant correlation between serum sICAM-1 levels and cognitive impairment. Analysis of serum IGF-1 levels in patients with SIVD may facilitate early identification of cognitive impairment, early intervention, delaying cognitive impairment in SIVD. IGF-1 may be a potential target for intervention of SIVD.